Latest news with #Ophthalmology
Yahoo
a day ago
- Business
- Yahoo
Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity
MarketNewsUpdates News Commentary NEW YORK, July 22, 2025 /CNW/ -- According to a report from Research And Markets, the AI in Ophthalmology Market was valued at USD 209.23 million in 2024, and is projected to reach USD 1.36 billion by 2030, rising at a CAGR of 36.79%. The rising prevalence of eye diseases, advancements in imaging technology, and expansion of teleophthalmology services are factors contributing to market growth. The report said: "In addition, growing preference for personalized treatment plans and increasing government initiatives fuel market growth further. The increasing prevalence of eye-related conditions, such as diabetic retinopathy, age-related macular degeneration (AMD), and glaucoma, is a significant factor driving the adoption of AI in ophthalmology. As the population ages, the incidence of these diseases increases, creating a need for efficient and accurate diagnostic tools. For instance, according to the CDC, the estimated number of Americans living with glaucoma in 2022 was 4.22 million. AI algorithms can rapidly analyze complex retinal images, facilitating early detection and treatment. For instance, AI systems have shown high sensitivity and specificity in identifying diabetic retinopathy, which allows for timely interventions and reduces the risk of vision loss. Moreover, integrating advanced imaging techniques such as Optical Coherence Tomography (OCT) with AI has revolutionized ophthalmic diagnostics. High-resolution imaging provides detailed views of ocular structures, which enhances diagnostic precision when analyzed by artificial intelligence (AI). The availability of large datasets from these imaging technologies allows for the training of robust AI models, improving their accuracy and reliability in clinical settings." Active healthcare/tech companies active in the diabetes treatment industry include: Avant Technologies Inc. (OTCQB: AVAI), Alcon Inc. (NYSE: ALC), Bausch + Lomb Corporation (NYSE: BLCO), Johnson & Johnson (NYSE: JNJ), Tempus AI, Inc. (NASDAQ: TEM). Research And Markets continued: "Furthermore, teleophthalmology, the remote delivery of eye care services, has gained traction, especially in underserved regions. AI is crucial in this expansion by enabling automated analysis of retinal images, facilitating remote diagnosis, and reducing the need for in-person consultations. This approach increases access to eye care and optimizes resource utilization in healthcare systems. For instance, in June 2024, C3 Med-Tech, an ophthalmic health tech startup, raised USD 0.23 million to launch AI-enabled, portable eye screening devices. The funding is expected to support telemedicine integration, real-time disease detection, and expansion across India, aiming to reduce avoidable blindness, especially in underserved communities facing a shortage of ophthalmologists. Moreover, AI's ability to analyze and interpret data from Electronic Health Records (EHRs) facilitates personalized treatment plans in ophthalmology. AI predicts disease progression by assessing patient history, genetic information, and imaging data and recommends tailored interventions, further contributing to market growth." Avant Technologies, Inc. (OTCQB: AVAI) Joint Venture Partner Presents AI Technology at Roche Ophthalmology Conference - Avant Technologies, Inc. ("Avant" or the "Company"), an emerging technology company developing healthcare solutions using both artificial intelligence (AI) and developments in biotechnology, today announced that Vinicio Vargas, Chief Executive Officer (CEO) of Avant's partner, Ainnova Tech, Inc., (Ainnova), was a featured speaker Friday and Saturday at Roche's Latin America "Macular Spectacular" Ophthalmology conference in Cartagena, Colombia. The conference highlighted the latest in scientific advances in treatments for the most common eye diseases, including age-related macular degeneration, diabetic macular edema, and diabetic retinopathy, while also focusing on strengthening collaboration between industry specialists in Latin America. Ainnova's CEO, Vinicio Vargas, who is also a member of the Board of Directors of Ai-nova Acquisition Corp. (AAC), the company formed by the partnership between Avant and Ainnova to advance and commercialize Ainnova's technology portfolio, discussed the status of AI and its uses in the industry to improve patient outcomes. Vargas and a host of renowned speakers that included Dr. Laura Velásquez, Dr. Roberto Gallego, Hugo Ocampo, and other ophthalmologists and experts presented the latest tools to transform visual health in the region, reflected on unmet needs, and explained how innovation can help build stronger, accessible, and patient-centered health systems. In Q4 2024, Ainnova entered a strategic alliance with global biotech, Roche, and leading pre-paid health plan provider, Salud 360, to start a pilot program to combat diabetic retinopathy using Ainnova's AI-powered, cutting-edge technology, Vision AI. The alliance aims at improving access to vision screening in patients with uncontrolled diabetes with the hope of decreasing the risks of diabetic retinopathy. If the program is successful, Avant and Ainnova hope to implement a similar program in the United States, Canada, and Europe through AAC. AAC has the worldwide licensing rights for Ainnova's technology portfolio, which includes Ainnova's Vision AI platform. CONTINUED… Read this and more news for Avant Technologies at: In other diabetes developments and happenings in the biotech market include: Alcon Inc. (NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, recently announced that UNITY® Vitreoretinal Cataract System (VCS) has received Health Canada approval. This innovation is the first to be introduced from Alcon's highly anticipated Unity portfolio. "Today marks an important day for Canadian ophthalmologists as we introduce the next generation of equipment solutions in cataract and vitreoretinal surgery, and we are grateful to those who helped us reach this milestone," said Franck Leveiller, Head of Global R&D and Chief Scientific Officer, Alcon. "We have a long legacy of engaging our customers throughout the research and development process to design bold innovations in ophthalmology. This approval is a significant milestone in delivering meaningful impact for Canadian Eye Care Professionals and patients." Bausch + Lomb Corporation (NYSE: BLCO), a leading global eye health company dedicated to helping people see better to live better, recently launched "Eyes Tell the Story: The Impact of Dry Eye." The campaign aims to educate about dry eye through personal stories, compelling imagery and new survey data, and encourages people with symptoms to speak with their eye doctor to find relief. Eyes Tell the Story builds upon Know Your Dry Eye, an educational campaign launched in 2024 that featured data and insights from the company's first State of Dry Eye survey, which showed the majority of Americans may not know that their eye symptoms are associated with eye dryness, despite the growing prevalence of dry eye. This year's survey, conducted among dry eye sufferers who are using either a prescription treatment or over-the-counter (OTC) product, further supports the need for more patient education and to dispel ongoing misconceptions surrounding dry eye. Johnson & Johnson (NYSE: JNJ) recently launched TECNIS Odyssey IOL in Europe, the Middle East, and Canada. The TECNIS Odyssey IOL was first launched in the US in October 2024. The TECNIS Odyssey IOL is a full vision range intraocular lens (IOL), built on the TECNIS platform from Johnson & Johnson, which, according to the company, provides 2 times better contrast in low lighting than PanOptix. The TECNIS Odyssey combines advanced optics and proprietary materials, offering consistently clear, high-contrast vision, according to the company. Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, recently announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-Low EF (ejection fraction) software, which uses AI to identify certain patients who may have a low left ventricular ejection fraction (LVEF). Tempus ECG-Low EF joins Tempus ECG-AF as the second FDA-cleared ECG-AI device in Tempus' growing suite of next generation devices designed to identify patients at risk for a variety of cardiovascular conditions. "With Tempus ECG-Low EF, we're adding another powerful tool to the hands of clinicians to help them identify patients at risk for serious cardiovascular conditions much earlier in their care journey," said Brandon Fornwalt, MD, PhD, Senior Vice President of Cardiology at Tempus. "Detection of LVEF is essential for undiagnosed patients, and this technology enables us to deliver that capability at scale to transform patient care. The addition of a second FDA-cleared Tempus ECG-AI solution reflects our continued commitment to advancing AI-driven cardiology." DISCLAIMER: (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU'S market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU was compensated forty nine hundred dollars for news coverage of the current press releases issued by Avant Technologies, Inc. by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and MNU undertakes no obligation to update such statements. Contact Information: Media Contact email: editor@ - +1(561)325-8757 View original content: SOURCE MarketNewsUpdates View original content: Sign in to access your portfolio
National Post
02-07-2025
- Business
- National Post
Innovia Medical Advances Strategic Vision with Acquisitions of Grace Medical and Hurricane Medical
Article content ST. PAUL, Minn. — Innovia Medical, a global medical device company focused on specialty surgical products, announced today the acquisitions of two well-respected specialty medical device companies: Grace Medical, a global leader in Ear, Nose, and Throat (ENT) solutions, and Hurricane Medical, a trusted provider of Ophthalmic surgical products. Article content These acquisitions mark a pivotal milestone in Innovia Medical's continued growth, reinforcing its commitment to building a globally integrated platform of specialty surgical solutions. By uniting distinct areas of expertise and synergistic product portfolios, Innovia Medical is expanding its clinical reach and strengthening its ability to support healthcare providers and patients worldwide. Article content Article content 'Grace Medical and Hurricane Medical have each built strong reputations within ENT and Ophthalmology, and we are proud to bring their expertise and talent into the Innovia Medical family,' said Terry Meredith, CEO of Innovia Medical. 'Grace Medical brings a leading portfolio of highly specialized ENT products that address complex surgical needs, while Hurricane Medical adds a complementary range of Ophthalmic solutions, backed by strong manufacturing capabilities and a deep commitment to customer service. Together, these additions strengthen our ability to deliver comprehensive, high-quality solutions that empower clinicians, improve patient care, and advance our vision for specialty surgical innovation.' Article content Grace Medical, headquartered in Memphis, TN, brings a strong portfolio of advanced ENT technologies and a legacy of clinical leadership. 'We look forward to expanding our ENT presence with Innovia Medical and continuing to service ENT customers around the world,' said Murray Beard, CEO of Grace Medical. Michael Crook, President, Chief Operating Officer of Grace Medical, will lead the strategic direction of the ENT division at Innovia Medical. Reflecting on the partnership, he shared: 'Joining forces with Innovia Medical brings together two highly complementary organizations – creating a world-class ENT platform with the scale, expertise, and product depth needed to better serve specialists and advance patient care.' Article content Hurricane Medical, based in Bradenton, FL, is a respected provider of high-quality Ophthalmic surgical solutions. 'We see a tremendous opportunity to grow Hurricane Medical's product coverage through Innovia Medical's commercial reach and global infrastructure,' said Dell Bauslaugh, President of Hurricane Medical. 'We are excited for what this means for our customers and our team.' Article content Customers and partners can expect continuity in operations, with the same sales and service contacts remaining in place. The integration of these organizations is expected to result in enhanced capabilities, increased resources, broader product portfolios, and a shared commitment to delivering outstanding outcomes for patients and clinicians alike. Article content Innovia Medical and its long-term growth strategy are backed by private investment firm Inverness Graham Investments. Article content About Innovia Medical Article content Article content Article content Contacts Article content Media Contact: Article content Article content Article content Article content
Yahoo
15-05-2025
- Business
- Yahoo
India Ophthalmic Devices Market Forecast Report 2025-2033, Competitive Analysis of Alcon, Bausch Health, Carl Zeiss, Meditec, Essilor, Hoya, Johnson & Johnson, Nidek, Topcon
The India Ophthalmology Devices Market is set to grow from USD 661.10 million in 2024 to USD 1.12 billion by 2033, at a CAGR of 6.11%. Key drivers include the rising prevalence of eye diseases, an aging population, and technological advances in ophthalmic devices. Government initiatives and increased healthcare spending further propel growth, while high costs and a lack of trained professionals pose challenges. Regional differences show growth in East, North, and South India with varying access levels and infrastructure development. Indian Ophthalmic Devices Market Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "India Ophthalmic Devices Market Size and Share Analysis - Growth Trends and Forecast Report 2025-2033" has been added to India Ophthalmology Devices Market is on a promising trajectory, projected to rise from USD 661.10 million in 2024 to USD 1.12 billion by 2033, expanding at a CAGR of 6.11% The surge is fueled by increasing eye disease incidences, the elders' growing demographic, and technological advancements in ophthalmic devices. Crucial drivers include the prevalence of cataracts, glaucoma, refractive errors, and diabetic retinopathy, escalating with an aging population and diabetes spread. Enhanced government measures like the National Programme for Control of Blindness (NPCB) and private investments in advancing ophthalmic technologies play pivotal roles. AI-enhanced diagnostics and teleophthalmology significantly extend access in rural regions, while awareness and cost reductions propel market demand. Significant market growth factors encompass the high occurrence of eye disorders in India and technological strides in ophthalmic equipment such as AI-based diagnostics, robotic surgeries, and advanced laser therapies. Breakthrough instruments like optical coherence tomography (OCT) and affordable intraocular lenses (IOLs) broaden the availability of cutting-edge ophthalmic care, enhancing early detection and treatment efficacy. C3 Med-Tech's investment in bringing AI-powered eye screening devices exemplifies such advancements. Government initiatives and rising healthcare investment are central to the market's expansion. The government drives accessibility through programs like the Ayushman Bharat scheme, sponsoring new ophthalmic facilities and insurance coverage increases. The 'Comprehensive Eye Care Programme' in Karnataka aims to benefit underprivileged populations, supported by efforts for innovative ocular devices and solutions. Challenges remain, with the high cost of advanced devices hindering widespread adoption, particularly in rural and semi-urban areas. Limited numbers of experienced ophthalmologists further dilute accessibility, although efforts in teleophthalmology and capacity-building persist. Within specific segments, the intraocular lenses market flourishes due to rising cataract surgeries, offering improved multifocal IOLs. Government initiatives for cost-effective IOLs and domestic production facilitate market growth against a backdrop of heightened cataract surgery awareness. The laser devices market benefits from precision surgeries like LASIK, despite the high costs, with technological development likely to spur future uptake. Demand for ophthalmoscopes and corneal topography systems escalates as conditions like diabetic retinopathy and keratoconus are diagnosed more frequently. Though cost and device availability challenge rural deployment, tech advancements push growth. Contact lenses enjoy increased demand for non-invasive vision correction, fueled by urban lifestyles and disposable income growth, even as educational gaps in lens care persist. The East, North, and South India markets each exhibit distinct growth patterns, supported by government investments, urban infrastructure, and renowned eye care institutions. Companies like Alcon Inc., Bausch Health Companies Inc., and Essilor International SA are instrumental market players deploying robust strategies across the ophthalmic landscape. As these trends unfold, the India Ophthalmology Devices Market is poised to significantly transform eye care services nationwide. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2024 - 2033 Estimated Market Value (USD) in 2024 $661.1 Million Forecasted Market Value (USD) by 2033 $1120 Million Compound Annual Growth Rate 6.1% Regions Covered India Key Topics Covered: 1. Introduction2. Research & Methodology3. Executive Summary4. Market Dynamics5. India Ophthalmic Devices Market6. Market Share7. Surgical Devices8. Diagnostic and Monitoring Devices9. Vision Correction Devices10. Region11. Porter's Five Analysis12. SWOT Analysis13. Company Analysis Alcon Inc. Bausch Health Companies Inc. Carl Zeiss Meditec AG Essilor International SA Hoya Corporation Johnson & Johnson Nidek Co. Ltd Topcon Corporation For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Indian Ophthalmic Devices Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Zawya
15-05-2025
- Health
- Zawya
Saudi Arabia hosts landmark Ophthalmology Meeting to advance (DME) and (RVO) Treatment
Under the title 'Holistic pro-Inflammatory Target for Sight (HITS)' the Ophthalmology Pivotal Meeting kicked off in Saudi Arabia on April 25, 2025, under the auspices of AbbVie, the global biopharmaceutical research and development company. This is a significant move to elevate the standard of care for various eye conditions like Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO). More than 100 national and international ophthalmologists participated in the meeting, which included scientific lectures and in-depth workshops to leverage applied medical specialties in ophthalmology and optics, exchange knowledge and expertise, and help change perspectives on the best ways to improve patient outcomes. It also discussed treatment and management methods of these prevalent diseases. In his lecture, Dr. Mattias Iglicki, Consultant Ophthalmologist, Vitreoretinal Surgeon and Researcher from University of Buenos Aires, Argentina, praised the convening of this meeting, which is a good opportunity to discuss the latest advancements and clinical trials in the presence of this elite group of international retinal specialists, along with local experts. He explained that diabetic macular edema, which is often the result of high blood sugar levels in diabetics, accompanied with leaky blood vessels leading to swelling in the retina. On the other hand, retinal vein occlusion occurs when the retinal veins are blocked, causing fluid buildup and impaired vision. Both conditions are serious and require proactive management to prevent the disease from worsening. Dr. Iglicki emphasized that organizing such medical summits and conferences serves as a platform for sharing and disseminating the cutting-edge research and developments in treating eye diseases, especially DME and RVO, which are diseases whose rates are increasing with the increasing incidence of diabetes. This enables the attending ophthalmologists to implement these updates in their practices, which in turn advances treatment methods in the Kingdom of Saudi Arabia in accordance with the latest international recommendations and technologies, thus improving the lives of patients and alleviating their daily suffering. For his part, Dr. Ashraf Daoud, General Manager of AbbVie Saudi Arabia, pointed out that Saudi Arabia's hosting of such medical meetings and seminars reflects the Kingdom's interest in promoting medical education and exchanging scientific expertise between international and local physicians to highlight the most important scientific and medical developments and provide distinguished medical care. By organizing this congress, AbbVie underscores its commitment to enhancing patient outcomes through educational initiatives and collaboration among eye care professionals. Sharing knowledge and expertise at such events is crucial to our ongoing efforts to refine treatment strategies, improve patients' quality of life, and help make a real difference in their lives. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio.
Zawya
15-05-2025
- Health
- Zawya
Saudi Arabia hosts landmark ophthalmology meeting to advance DME and RVO treatment
Under the title 'Holistic pro-Inflammatory Target for Sight (HITS)' the Ophthalmology Pivotal Meeting kicked off in Saudi Arabia on April 25, 2025, under the auspices of AbbVie, the global biopharmaceutical research and development company. This is a significant move to elevate the standard of care for various eye conditions like Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO). More than 100 national and international ophthalmologists participated in the meeting, which included scientific lectures and in-depth workshops to leverage applied medical specialties in ophthalmology and optics, exchange knowledge and expertise, and help change perspectives on the best ways to improve patient outcomes. It also discussed treatment and management methods of these prevalent diseases. In his lecture, Dr. Mattias Iglicki, Consultant Ophthalmologist, Vitreoretinal Surgeon and Researcher from University of Buenos Aires, Argentina, praised the convening of this meeting, which is a good opportunity to discuss the latest advancements and clinical trials in the presence of this elite group of international retinal specialists, along with local experts. He explained that diabetic macular edema, which is often the result of high blood sugar levels in diabetics, accompanied with leaky blood vessels leading to swelling in the retina. On the other hand, retinal vein occlusion occurs when the retinal veins are blocked, causing fluid buildup and impaired vision. Both conditions are serious and require proactive management to prevent the disease from worsening. Dr. Iglicki emphasized that organizing such medical summits and conferences serves as a platform for sharing and disseminating the cutting-edge research and developments in treating eye diseases, especially DME and RVO, which are diseases whose rates are increasing with the increasing incidence of diabetes. This enables the attending ophthalmologists to implement these updates in their practices, which in turn advances treatment methods in the Kingdom of Saudi Arabia in accordance with the latest international recommendations and technologies, thus improving the lives of patients and alleviating their daily suffering. For his part, Dr. Ashraf Daoud, General Manager of AbbVie Saudi Arabia, pointed out that Saudi Arabia's hosting of such medical meetings and seminars reflects the Kingdom's interest in promoting medical education and exchanging scientific expertise between international and local physicians to highlight the most important scientific and medical developments and provide distinguished medical care. By organizing this congress, AbbVie underscores its commitment to enhancing patient outcomes through educational initiatives and collaboration among eye care professionals. Sharing knowledge and expertise at such events is crucial to our ongoing efforts to refine treatment strategies, improve patients' quality of life, and help make a real difference in their lives. About AbbVie AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, oncology, neuroscience, and eye care – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at Follow @abbvie on LinkedIn, Facebook, Instagram, X and YouTube.
